Trial Profile
A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Nichiiko Pharmaceutical
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2012 New trial record